Ask what GHK-Cu is and you will be told it's a copper peptide used in skincare. That's a fair description of where it ended up. It has almost nothing to do with where it started.
In 1973, Pickart and Thaler reported a tripeptide they had isolated from human serum. Blood, not skin. What they described it doing was prolonging the survival of cultured normal liver cells.
That's the whole of the origin story. A short peptide pulled out of blood, tested on liver cells in a dish, in a paper that mentions neither collagen nor cosmetics. Even the copper isn't in it yet. The material now sold as GHK-Cu is the copper-bound form, and that pairing was worked out afterward.
Through the late 1970s and early 1980s, researchers established that the peptide binds copper tightly and worked out which parts of the molecule hold the metal. This is the period that turned GHK into GHK-Cu.
One result from those years is still a nice piece of scientific humility. A 1982 study examining the complex in solution found that the shape the molecule adopts as a solid crystal does not survive being dissolved. The structure you would draw from the crystal is not the structure in the tube. It's a useful reminder that a diagram and a solution are different things, and the current identity record for the compound sits on its molecular profile.
Two accounts of the peptide's job emerged, and they point in opposite directions.
One is delivery: the complex carries copper into the cellular environment, where copper is needed as a cofactor by enzymes that assemble connective tissue. The other is buffering: the metal-free peptide mops up loose copper and damps down its reactivity, which is a scavenging role rather than a courier one.
Whether either applies to a given experiment depends on whether the peptide arrived already carrying copper, and the literature has been blurry about that distinction for decades.
Early solution work complicated the delivery story in a specific way. It found that GHK and copper don't form one tidy complex, but several species at once. It also found the peptide competing with albumin, another protein present in blood, rather than dominating it. A later binding measurement found albumin's own copper site holds copper somewhat more tightly than GHK does.
Neither result rules delivery out. They just mean the obvious version of the story, that this peptide exists to ferry copper about, is less obvious than it sounds.
The connective-tissue work that made the compound famous begins in 1988, a full fifteen years after the discovery paper. A French group reported that the copper complex increased collagen production in cultured fibroblasts, and specified that the rise was not explained by there simply being more cells present. Ruling out the boring explanation is what makes that result worth citing.
A 1992 follow-up was more precise still. The complex raised synthesis of certain sulfated components of the connective-tissue scaffold, while leaving hyaluronic acid, which isn't sulfated, unaffected. A narrow claim like that is more useful than a broad one, because a narrow claim can be checked.
Work in 2000 added a further wrinkle, reporting effects on matrix turnover rather than only on deposition. That's where the description of the peptide as balancing breakdown against assembly comes from. Those fibroblasts were rat rather than human, a detail the original authors recorded and secondary write-ups tend to lose.
This is the era that built the modern reputation, and it's why the compound now sits in a dermal range rather than anywhere near liver research.
The cosmetic career eventually produced relatives of its own. Pal-GHK is the same three amino acids carrying a fatty chain and no copper whatsoever. It's a molecule that exists because of where GHK ended up, not because of anything in the 1973 paper.
In 2012, a group derived a gene signature from diseased human lung tissue and GHK came out of the screen as a molecule predicted to reverse it. In 2022, a different group surfaced it independently through network modeling in Alzheimer's disease.
Neither team was hunting for a skincare ingredient. Both worked with the metal-free peptide rather than the copper complex, which is worth knowing before reading either as evidence about the material sold under the copper name.
Fifty years on, the molecule keeps reappearing in fields with no connection to the one it's best known for.
The most repeated biographical fact about this peptide is that its concentration in blood falls with age, usually accompanied by two specific numbers, one for a young adult and a much lower one for someone in their sixties.
We mention the observation in our review of the GHK-Cu literature and we leave the numbers out. The figures in general circulation trace to a review that gives no supporting primary citation for them. A number repeated often enough begins to feel measured, and that one isn't, or at least isn't traceably so.
It's a small thing, but it's the kind of small thing that separates a compound's actual history from its marketing biography.
Blood, then copper chemistry, then connective tissue, then lung and brain gene signatures. That's the sequence, and skin is not the beginning of it. It's a chapter in the middle that happened to get all the attention, arriving fifteen years after the molecule itself and staying long enough to become the whole public identity.
The 1973 paper is still there, describing a tripeptide from human serum and some liver cells in a dish.
GHK-Cu is a research compound, supplied for laboratory research use only.
MOTS-c sits inside a mitochondrial gene whose job was never to make proteins. The discovery story, and what a sequence in a database does and doesn't prove.
A convincing blue color is easy to fake. Here's the plain-English version of the two checks that actually prove GHK-Cu's copper is real.
